Elan Corp considered buying New York investment firm Royalty Pharma last year, about six months before Royalty Pharma turned around with an acquisition proposal for Elan that’s now valued at about $5.7bn (€4.33bn).

A young man is fighting for his life because the HSE has refused to fund a trip to New York for a “one last chance” treatment.